10-Q 1 icui0930201710-q.htm ICUI 09.30.2017 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2017
Or

o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: to
Commission File No.: 001-34634
ICU MEDICAL, INC.
(Exact name of Registrant as specified in its charter)

Delaware |  | 33-0022692
(State or other jurisdiction of |  | (I.R.S. Employer
incorporation or organization) |  | Identification No.)

951 Calle Amanecer, San Clemente, California |  | 92673
(Address of principal executive offices) |  | (Zip Code)

(949) 366-2183
(Registrant’s telephone number including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer x |  | Accelerated filer o
Non-accelerated filer o |  | Smaller reporting company o
(Do not check if a smaller reporting company) |  | Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class |  | Outstanding at October 31, 2017
Common |  | 20,130,535

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x

ICU MEDICAL, INC. AND SUBSIDIARIES Form 10-Q September 30, 2017 Table of Contents
PART I. | Financial Information |  | Page Number
Item 1. | Financial Statements (Unaudited) |  |
| Condensed Consolidated Balance Sheet, at September 30, 2017 and December 31, 2016 |  | 3
| Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016 |  | 4
| Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2017 and 2016 |  | 5
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 |  | 6
| Notes to Condensed Consolidated Financial Statements |  | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 25
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |  | 40
Item 4. | Controls and Procedures |  | 41
PART II. | Other Information |  |
Item 1. | Legal Proceedings |  | 41
Item1A. | Risk Factors |  | 42
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |  | 42
Item 6. | Exhibits |  | 43
| Signature |  | 44

2

PART I - FINANCIAL INFORMATION

Item1. | Financial Statements (Unaudited)

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value data)

| September 30, 2017 |  | December 31, 2016
| (Unaudited) |  | (1)
ASSETS |  |  |
CURRENT ASSETS: |  |  |  |  |
Cash and cash equivalents | $ | 300,614 |  |  | $ | 445,082 |
Short-term investment securities | 9,591 |  |  | — |
TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES | 310,205 |  |  | 445,082 |
Accounts receivable, net of allowance for doubtful accounts of $3,256 at September 30, 2017 and $1,073 at December 31, 2016 | 105,090 |  |  | 56,161 |
Inventories | 320,341 |  |  | 49,264 |
Income tax receivable | 12,105 |  |  | 11,235 |
Prepaid expenses and other current assets | 146,471 |  |  | 7,355 |
Assets held-for-sale | 12,489 |  |  | — |
TOTAL CURRENT ASSETS | 906,701 |  |  | 569,097 |
PROPERTY AND EQUIPMENT, net | 390,526 |  |  | 85,696 |
LONG-TERM INVESTMENT SECURITIES | 15,140 |  |  | — |
GOODWILL | 6,687 |  |  | 5,577 |
INTANGIBLE ASSETS, net | 152,338 |  |  | 22,383 |
DEFERRED INCOME TAXES | 16,390 |  |  | 21,935 |
OTHER ASSETS | 35,192 |  |  | — |
TOTAL ASSETS | $ | 1,522,974 |  |  | $ | 704,688 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |
CURRENT LIABILITIES: |  |  |  |  |
Accounts payable | $ | 44,685 |  |  | $ | 14,641 |
Accrued liabilities | 146,147 |  |  | 25,896 |
Income tax liability | 4,263 |  |  | — |
TOTAL CURRENT LIABILITIES | 195,095 |  |  | 40,537 |
CONTINGENT EARN-OUT LIABILITY | 32,000 |  |  | — |
LONG-TERM OBLIGATIONS | 75,000 |  |  | — |
OTHER LONG-TERM LIABILITIES | 68,034 |  |  | 1,107 |
DEFERRED INCOME TAXES | 9,491 |  |  | 1,370 |
INCOME TAX LIABILITY | 1,519 |  |  | 1,519 |
COMMITMENTS AND CONTINGENCIES | — |  |  | — |
STOCKHOLDERS’ EQUITY: |  |  |  |  |
Convertible preferred stock, $1.00 par value Authorized—500 shares; Issued and outstanding— none | — |  |  | — |
Common stock, $0.10 par value — Authorized, 80,000 shares; Issued and Outstanding, 20,021 shares at September 30, 2017 and 16,338 shares at December 31, 2016 | 2,002 |  |  | 1,633 |
Additional paid-in capital | 607,694 |  |  | 162,828 |
Treasury stock, at cost | (2 | ) |  | (14 | )
Retained earnings | 535,919 |  |  | 516,980 |
Accumulated other comprehensive loss | (3,778 | ) |  | (21,272 | )
TOTAL STOCKHOLDERS' EQUITY | 1,141,835 |  |  | 660,155 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 1,522,974 |  |  | $ | 704,688 |

______________________________________________________
(1) December 31, 2016 balances were derived from audited consolidated financial statements.
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Table of Contents
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share data)

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
REVENUE: |  |  |  |  |  |  |  |  |
Net sales | $ | 343,084 |  |  | $ | 97,098 |  |  | $ | 921,544 |  |  | $ | 283,659 |
Other | 152 |  |  | 10 |  |  | 945 |  |  | 25 |
TOTAL REVENUE | 343,236 |  |  | 97,108 |  |  | 922,489 |  |  | 283,684 |
COST OF GOODS SOLD | 231,638 |  |  | 45,835 |  |  | 633,884 |  |  | 133,046 |
GROSS PROFIT | 111,598 |  |  | 51,273 |  |  | 288,605 |  |  | 150,638 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |
Selling, general and administrative | 76,820 |  |  | 22,362 |  |  | 226,812 |  |  | 66,828 |
Research and development | 12,769 |  |  | 3,650 |  |  | 37,377 |  |  | 10,301 |
Restructuring, strategic transaction and integration | 18,711 |  |  | 2,806 |  |  | 68,033 |  |  | 4,339 |
Change in fair value of earn-out | 7,000 |  |  | — |  |  | 13,000 |  |  | — |
TOTAL OPERATING EXPENSES | 115,300 |  |  | 28,818 |  |  | 345,222 |  |  | 81,468 |
(LOSS) INCOME FROM OPERATIONS | (3,702 | ) |  | 22,455 |  |  | (56,617 | ) |  | 69,170 |
BARGAIN PURCHASE GAIN | 8,534 |  |  | 346 |  |  | 71,771 |  |  | 1,456 |
INTEREST EXPENSE | (705 | ) |  | (58 | ) |  | (1,743 | ) |  | (135 | )
OTHER INCOME (EXPENSE) | 583 |  |  | 283 |  |  | (2,030 | ) |  | 584 |
INCOME BEFORE INCOME TAXES | 4,710 |  |  | 23,026 |  |  | 11,381 |  |  | 71,075 |
(PROVISION) BENEFIT FOR INCOME TAXES | (4,574 | ) |  | (4,220 | ) |  | 7,558 |  |  | (17,503 | )
NET INCOME | $ | 136 |  |  | $ | 18,806 |  |  | $ | 18,939 |  |  | $ | 53,572 |
NET INCOME PER SHARE |  |  |  |  |  |  |  |  |
Basic | $ | 0.01 |  |  | $ | 1.16 |  |  | $ | 0.97 |  |  | $ | 3.32 |
Diluted | $ | 0.01 |  |  | $ | 1.09 |  |  | $ | 0.92 |  |  | $ | 3.13 |
WEIGHTED AVERAGE NUMBER OF SHARES |  |  |  |  |  |  |  |  |
Basic | 19,984 |  |  | 16,200 |  |  | 19,433 |  |  | 16,113 |
Diluted | 21,106 |  |  | 17,286 |  |  | 20,603 |  |  | 17,100 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Table of Contents
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)
(In thousands)

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
NET INCOME | $ | 136 |  |  | $ | 18,806 |  |  | $ | 18,939 |  |  | $ | 53,572 |
Other comprehensive income, net of tax: |  |  |  |  |  |  |
Cash flow hedge adjustments, net of taxes of $82 and $(603) for the three and nine months ended September 30, 2017, respectively | (134 | ) |  | — |  |  | 985 |  |  | — |
Foreign currency translation adjustment, net of taxes of $0 and $(19) for the three months ended September 30, 2017 and 2016, respectively, and $56 and $394 for the nine months ended September 30, 2017 and 2016, respectively | 5,833 |  |  | 700 |  |  | 16,747 |  |  | 2,532 |
Other adjustments, net of taxes of $0 for all periods | (90 | ) |  | — |  |  | (238 | ) |  | — |
Other comprehensive income, net of taxes | 5,609 |  |  | 700 |  |  | 17,494 |  |  | 2,532 |
TOTAL COMPREHENSIVE INCOME | $ | 5,745 |  |  | $ | 19,506 |  |  | $ | 36,433 |  |  | $ | 56,104 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Table of Contents
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands)

| Nine Months Ended September 30,
| 2017 |  | 2016
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |
Net income | $ | 18,939 |  |  | $ | 53,572 |
Adjustments to reconcile net income to net cash (used in) provided by operating activities: |  |  |  |
Depreciation and amortization | 47,512 |  |  | 14,351 |
Provision for doubtful accounts | 1,906 |  |  | — |
Provision for warranty and returns | 3,639 |  |  | (22 | )
Stock compensation | 13,387 |  |  | 11,464 |
Loss on disposal of property and equipment | 3,177 |  |  | 40 |
Bond premium amortization | 12 |  |  | 1,026 |
Bargain purchase gain | (71,771 | ) |  | (1,456 | )
Change in fair value of earn-out | 13,000 |  |  | — |
Other | 1,690 |  |  | 69 |
Changes in operating assets and liabilities, net of effects of acquisitions: |  |  |  |
Accounts receivable | (51,498 | ) |  | 4,736 |
Inventories | 148,482 |  |  | (6,635 | )
Prepaid expenses and other assets | (125,403 | ) |  | (2,228 | )
Accounts payable | 17,551 |  |  | (1,587 | )
Accrued liabilities | 63,234 |  |  | (7,314 | )
Income taxes, including excess tax benefits and deferred income taxes | (13,982 | ) |  | 2,691 |
Net cash provided by operating activities | 69,875 |  |  | 68,707 |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |
Purchases of property and equipment | (51,702 | ) |  | (15,018 | )
Proceeds from sale of asset | 2 |  |  | 1 |
Business acquisitions, net of cash acquired | (157,097 | ) |  | (2,584 | )
Intangible asset additions | (3,718 | ) |  | (861 | )
Purchases of investment securities | (24,743 | ) |  | (111,575 | )
Proceeds from sale of investment securities | — |  |  | 45,429 |
Net cash used in investing activities | (237,258 | ) |  | (84,608 | )
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |
Proceeds from exercise of stock options | 19,967 |  |  | 15,830 |
Proceeds from employee stock purchase plan | 2,705 |  |  | 2,361 |
Purchase of treasury stock | (3,951 | ) |  | (17,155 | )
Net cash provided by financing activities | 18,721 |  |  | 1,036 |
Effect of exchange rate changes on cash | 4,194 |  |  | 1,664 |
NET DECREASE CASH AND CASH EQUIVALENTS | (144,468 | ) |  | (13,201 | )
CASH AND CASH EQUIVALENTS, beginning of period | 445,082 |  |  | 336,164 |
CASH AND CASH EQUIVALENTS, end of period | $ | 300,614 |  |  | $ | 322,963 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Table of Contents
ICU MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED
(In thousands)

| Nine months ended September 30,
| 2017 |  | 2016
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES: |  |  |
Accounts payable for property and equipment | $ | 1,435 |  |  | $ | 595 |
Detail of acquisitions: |  |  |
Fair value of assets acquired | $ | 893,582 |  |  | $ | 4,081 |
Cash paid for acquisitions, net of cash acquired | (157,097 | ) |  | (2,584 | )
Non-cash seller note | (75,000 | ) |  | — |
Estimated working capital adjustment | 7,512 |  |  | — |
Contingent consideration | (19,000 | ) |  | — |
Issuance of common stock | (413,139 | ) |  | — |
Bargain purchase gain | (71,771 | ) |  | (1,456 | )
Goodwill | 1,015 |  |  | (775 | )
Liabilities assumed | $ | 166,102 |  |  | $ | (734 | )

The accompanying notes are an integral part of these consolidated financial statements.
7

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Note 1: | Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.") and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU Medical, Inc., ("ICU") a Delaware corporation, filed with the SEC for the year ended December 31, 2016.
We are engaged in the development, manufacturing and sale of innovative medical devices used in infusion therapy, and critical care markets. We sell the majority of our products through our direct sales force and through independent distributors throughout the U. S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. All subsidiaries are wholly owned and are included in the condensed consolidated financial statements. All intercompany balances and transactions have been eliminated.
Certain prior year amounts have been reclassified to conform to the current period’s presentation. These reclassifications had no impact on previously reported results of operations.
Note 2: New Accounting Pronouncements
Recently Adopted Accounting Standards
In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory within the scope of the ASU (e.g. FIFO or average cost) from lower of cost or market to lower of cost and net realizable value ("NRV"). NRV is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Prior to the ASU, U.S. generally accepted accounting principles required an entity to measure inventory at the lower of cost or market. Market is measured using replacement cost unless it is above NRV (commonly referred to as “ceiling”) or below NRV less an approximately normal profit margin (commonly referred to as “floor”). For inventory within its scope, the ASU eliminates the notions of replacement cost and NRV less a normal profit margin, which is intended to simplify the accounting for inventory. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. We adopted this ASU on January 1, 2017. This ASU did not have a material impact on our consolidated financial statements.
Recently Issued Accounting Standards
In August, 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The amendments in this update change both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results to facilitate financial reporting that more closely reflects an entity's risk management activities. The amendments in this update also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. The amendments are effective for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2018. For cash flow and net investment hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year that an entity adopts the update. This ASU is not expected to have a material impact on our consolidated financial statements or related footnote disclosures.
In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the ASU, an entity will account for the effects of a modification unless (i) the fair value of the modified award is the same as the fair value of the original award
8

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
immediately before the original award is modified, (ii) the vesting conditions of the modified award are the same vesting conditions as the original award immediately before the original award is modified, and (iii) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments in this ASU are effective prospectively for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. This ASU is not expected to have a material impact on our consolidated financial statements or related footnote disclosures.
In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This ASU is not expected to have a material impact on our consolidated financial statements or related footnote disclosures.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when a set (integrated set of assets and activities) is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. The amendments in ASU 2017-01 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The amendments in this ASU should be applied prospectively on or after the effective date. This ASU is not expected to have a material impact on our consolidated financial statements or related disclosures.
In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition, accordingly an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of an annual reporting period. The amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. This ASU is not expected to have a material impact on our consolidated financial statements or related disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December
9

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. This ASU is not expected to have a material impact on our consolidated financial statements or related disclosures.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above. We previously disclosed that we did not anticipate a material impact on our consolidated financial statements from adoption of any of the above. In light of the Hospira Infusion Systems ("HIS") acquisition we are still evaluating the impact of this ASU on our Infusion Systems revenue. We expect to have enhanced disclosures upon adoption of this ASU. We now expect to adopt the modified restrospective method when adopting this ASU.
Note 3: Acquisition, Strategic Transaction and Integration Expenses
Acquisitions
On February 1, 2017, we acquired 100% interest in Fannin (UK) Limited ("Fannin") for total consideration of approximately $1.5 million. Fannin provides infusion therapy consumable products to the healthcare sector in the United Kingdom and Ireland.
On February 3, 2017, we acquired 100% interest in Pfizer Inc.’s (“Pfizer”) HIS business for total cash consideration of approximately $260.0 million (net of estimated working capital adjustments paid at closing), which was financed with existing cash balances and a $75 million three-year interest-only seller note. We also issued 3.2 million shares of our common stock. The fair value of the common shares issued to Pfizer was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period whereby Pfizer cannot transfer the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement or (ii) eighteen months from the closing date. Additionally, Pfizer also may be entitled up to an additional $225 million in cash contingent consideration based on the achievement of performance targets for the combined company for the three years ending December 31, 2019 ("Earnout Period"). In the event that the sum of our Adjusted EBITDA as defined in the Amended and
10

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Restated Stock and Asset Purchase Agreement between us and Pfizer (the “HIS Purchase Agreement”) for the three years in the Earnout Period (the "Cumulative Adjusted EBITDA") is equal to or exceeds approximately $1 billion ("the "Earnout Target"), then Pfizer will be entitled to receive the full amount of the earnout. In the event that the Cumulative Adjusted EBITDA is equal to or greater than 85% of the Earnout Target (but less than the Earnout Target), Pfizer will be entitled to receive the corresponding percentage of the earnout. In the event that the Cumulative Adjusted EBITDA is less than 85% of the Earnout Target, then no earnout amount will be earned by Pfizer. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. We believe that the acquisition of the HIS business, which includes IV pumps, solutions and consumable devices complements our pre-existing business by creating a company that has a complete infusion therapy product portfolio. We believe that the acquisition significantly enhances our global footprint and platform for continued competitiveness and growth.
With the acquisition of HIS, pre-existing long-term supply and distribution contracts between ICU and HIS were effectively terminated.
Deferred Closings
In the HIS Purchase Agreement, we agreed with Pfizer to defer the local closing of the HIS business in certain foreign jurisdictions (the “Deferred Closing Businesses”) for periods ranging by jurisdiction from 3 to 12 months after the February 3, 2017 closing date (the "Deferred Closing Period"). The net assets in these jurisdictions represent an immaterial portion of the total HIS business net assets.
At the February 3, 2017 HIS business transaction closing, we entered into a Net Economic Benefit Agreement with Pfizer under which we agreed that (i) during the Deferred Closing Period, the economic benefits and burdens of the Deferred Closing Businesses are for our account, and we are to be treated as the beneficial owner of the Deferred Closing Businesses and (ii) Pfizer would continue to operate the Deferred Closing Businesses under our direction.
Preliminary Purchase Price
The following table summarizes the preliminary purchase price, subject to working capital adjustments, and the preliminary allocation of the purchase price related to the assets and liabilities purchased (in thousands):
11

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Estimated cash consideration for acquired assets |  | $ | 177,527 |
Fair value of Seller Note |  | 75,000 |
Preliminary fair value of contingent consideration payable to Pfizer (long-term) |  | 19,000 |
Issuance of ICU Medical, Inc. common shares: |  |
Number of shares issued to Pfizer |  | 3,200 |
Price per share (ICU's trading closing share price on the Closing Date) |  | $ | 140.75 |
Fair value of ICU shares issued to Pfizer |  | $ | 450,400 |
Less: Preliminary discount due to lack of marketability of 8.3% |  | (37,261 | )
Equity portion of purchase price |  | 413,139 |
Total estimated consideration to be paid |  | $ | 684,666 |
Preliminary Purchase Price Allocation: |  |
Cash and cash equivalents |  | $ | 29,475 |
Trade receivables |  | 362 |
Inventories |  | 417,470 |
Prepaid expenses and other assets |  | 17,255 |
Property and equipment |  | 295,694 |
Intangible assets(1) |  | 131,000 |
Other assets |  | 31,283 |
Accounts payable |  | (12,381 | )
Accrued liabilities |  | (54,794 | )
Long-term liabilities(2) |  | (68,510 | )
Total identifiable net assets acquired |  | $ | 786,854 |
Deferred tax liability |  | (30,417 | )
Estimated Gain on Bargain Purchase |  | (71,771 | )
Estimated Purchase Consideration |  | $ | 684,666 |

______________________________
(1) Preliminary identifiable intangible assets includes $48 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D has an indefinite life until the associated research and development efforts are complete.
(2) Preliminary long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.
The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration to be paid resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, we reassessed the methods used in the purchase accounting and verified that we had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. We also reevaluated the fair value of the contingent consideration transferred to determine that it was appropriate. We determined that the bargain purchase gain was primarily attributable to expected restructuring costs as well as a reduction to the initially agreed upon transaction price caused primarily by revenue shortfalls across all market segments of the HIS business, negative manufacturing variance due to the drop in revenue and higher operating and required stand up costs, when compared to forecasts of the HIS business at the time that the purchase price was agreed upon. After the continuing review of the product demand and operations of the HIS Business, including the resulting expected restructuring activities, we forecasted our estimated Adjusted EBITDA from the HIS business in 2017 to be
12

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
$35 million - $40 million, which is considerably lower than the forecast contemplated in initial negotiations with Pfizer, which resulted in an estimated fair value of $19 million related to the $225 million earn out. Restructuring costs, if incurred, would be expensed in future periods, see (Note 4: Restructuring Charges). The bargain purchase gain is separately stated below income from operations in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2017.
The above purchase price and purchase price allocation are preliminary and subject to future revision as the acquired assets and liabilities assumed are dependent upon the finalization of the related valuations.
The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair market value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and estimated useful lives. Fixed assets were valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence, the work in process was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.
We did not disclose the proforma revenue and earnings information required by ASC 805, Business Combinations as preparation of the information was not practicable. The HIS business is a carve-out of Pfizer's business and the standalone data for the prior year reporting period was not available.
Strategic Transaction and Integration Expenses
We incurred and expensed $15.5 million and $49.0 million in transaction and integration costs during the three and nine months ended September 30, 2017, respectively primarily related to our acquisition of the HIS business. These costs primarily related to consulting, legal and the transitional service agreement. We incurred $2.4 million and $3.5 million in transaction costs during the three and nine months ended September 30, 2016, respectively. The transaction costs were related to initial costs incurred on our acquisition of HIS, to our 2015 acquisition of EXC Holding Corp. and to our second quarter 2016 acquisition of Tangent Medical Technologies, Inc.
Note 4: Restructuring Charges
During the nine months ended September 30, 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 3: Acquisition, Strategic Transaction and Integration Expenses). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. We expect to complete these restructuring activities by the end of 2017. All material charges in regard to these restructuring activities have been incurred as of September 30, 2017.
During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.
The following table summarizes the details of changes in our restructuring-related accrual for the period ending September 30, 2017 (in thousands):
13

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

| Accrued Balance December 31, 2016 |  | Charges Incurred |  | Payments |  | Other Adjustments |  | Accrued Balance September 30, 2017
Severance pay and benefits | $ | 53 |  |  | $ | 14,600 |  |  | $ | (12,010 | ) |  | $ | (17 | ) |  | $ | 2,626 |
Employment agreement buyout | 1,477 |  |  | — |  |  | (273 | ) |  | — |  |  | 1,204 |
Facility closure expenses | — |  |  | 4,410 |  |  | (2,458 | ) |  | (1,952 | ) |  | — |
| $ | 1,530 |  |  | $ | 19,010 |  |  | $ | (14,741 | ) |  | $ | (1,969 | ) |  | $ | 3,830 |

Note 5: Net Income Per Share
Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock are not included in the treasury stock method calculation. There were 48 and 590 anti-dilutive securities for the three and nine months ended September 30, 2017, respectively. There were no anti-dilutive securities for the three and nine months ended September 30, 2016.
The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
Net income | $ | 136 |  |  | $ | 18,806 |  |  | $ | 18,939 |  |  | $ | 53,572 |
Weighted-average number of common shares outstanding (for basic calculation) | 19,984 |  |  | 16,200 |  |  | 19,433 |  |  | 16,113 |
Dilutive securities | 1,122 |  |  | 1,086 |  |  | 1,170 |  |  | 987 |
Weighted-average common and common equivalent shares outstanding (for diluted calculation) | 21,106 |  |  | 17,286 |  |  | 20,603 |  |  | 17,100 |
EPS — basic | $ | 0.01 |  |  | $ | 1.16 |  |  | $ | 0.97 |  |  | $ | 3.32 |
EPS — diluted | $ | 0.01 |  |  | $ | 1.09 |  |  | $ | 0.92 |  |  | $ | 3.13 |

Note 6: Derivatives And Hedging Activities
Hedge Accounting and Hedging Program
During the second quarter of 2017, we implemented a cash flow hedging program. The purpose of our hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.
In May 2017, we entered into a two-year cross-currency par forward contract to hedge a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instrument is recorded at fair value on the condensed consolidated balance sheets and is classified based on the instrument's maturity date. We record changes in the intrinsic value of the effective portion of the gain or loss on the derivative instrument as a component of Other Comprehensive Income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Any gain or loss on the derivative instrument due to ineffectiveness of the hedge will be recognized in the Condensed Consolidated Statements of Operations during the current period. The total notional amount of our outstanding derivative as of September 30, 2017 was approximately 600.3 million MXN. The term of our currency forward contract is May 1, 2017 to May
14

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
1, 2019. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 20.01 MXN/USD over the term of the two-year contract.
The following table presents the fair values of our derivative instrument included within the Condensed Consolidated Balance Sheet as of September 30, 2017 and December 31, 2016 (in thousands):

| Asset Derivatives
| Condensed Consolidated Balance Sheet Location |  | September 30, 2017 |  | December 31, 2016
Derivatives designated as cash flow hedging instruments |  |  |  |  |
Foreign exchange forward contract: | Prepaid expenses and other current assets |  | $ | 1,279 |  |  | $ | — |
| Other assets |  | 309 |  |  | — |
Total derivatives designated as cash flow hedging instruments |  |  | $ | 1,588 |  |  | $ | — |

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (in thousands):

|  | Line Item in the Condensed Consolidated Statements of Operations |  | Three months ended September 30, |  | Nine Months Ended September 30,
|  |  | 2017 |  | 2016 |  | 2017 |  | 2016
Derivatives designated as cash flow hedging instruments |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | Cost of goods sold |  | $ | 534 |  |  | — |  |  | $ | 556 |  |  | — |

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):

|  | Amount of Gain Recognized in Other Comprehensive Income on Derivatives |  | Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
|  | Three months ended September 30, |  |  |  | Three months ended September 30,
|  | 2017 |  | 2016 |  | Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income |  | 2017 |  | 2016
Derivatives designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contract |  | $ | 318 |  |  | $ | — |  |  | Cost of goods sold |  | $ | 534 |  |  | $ | — |
Total derivatives designated as cash flow hedging instruments |  | $ | 318 |  |  | $ | — |  |  |  |  | $ | 534 |  |  | $ | — |

As of September 30, 2017, we expect approximately $1.3 million of the deferred gains on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.
15

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

|  | Amount of Gain Recognized in Other Comprehensive Income on Derivatives |  | Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
|  | Nine Months Ended September 30, |  |  |  | Nine Months Ended September 30,
|  | 2017 |  | 2016 |  | Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income |  | 2017 |  | 2016
Derivatives designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contract |  | $ | 2,144 |  |  | $ | — |  |  | Cost of goods sold |  | $ | 556 |  |  | $ | — |
Total derivatives designated as cash flow hedging instruments |  | $ | 2,144 |  |  | $ | — |  |  |  |  | $ | 556 |  |  | $ | — |

Note 7: Fair Value Measurement
Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value:

• | Level 1: quoted prices in active markets for identical assets or liabilities;

• | Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

• | Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

During the first quarter of 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer may be entitled up to $225 million in cash if certain performance targets for the combined company for the three years ending December 31, 2019 are achieved. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The initial value assigned to the contingent consideration was a result of forecasted product demand of our HIS business, as discussed further in Note 3: Acquisition, Strategic Transaction and Integration Expenses. At each reporting date subsequent to the acquisition we will remeasure the earn-out using the same methodology above and recognize any changes in value. If the probability of achieving the performance target significantly changes from what we initially anticipated, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our condensed consolidated balance sheets.
The following table provides a reconciliation of the Level 3 earn-out liability measured at estimated fair value based on an initial valuation and updated quarterly for the nine months ended September 30, 2017 (in thousands):

|  | Earn-out Liability
Accrued balance, December 31, 2016 |  | $ | — |
Acquisition date fair value estimate of earn-out |  | 19,000 |
Change in fair value of earn-out (included in (loss) income from operations as a separate line item) |  | 13,000 |
Accrued balance, September 30, 2017 |  | $ | 32,000 |

The fair value of the earn-out at September 30, 2017 changed from the fair value calculated at acquisition due to a change in the forecast of the underlying target, adjusted EBITDA, and due to changes in other assumptions used in the Monte Carlo simulation, as detailed in the below table.
16

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table provides quantitative information about Level 3 inputs for fair value measurement of our earn-out liability as of the acquisition date and September 30, 2017. Significant increases or decreases in these inputs in isolation could result in a significant impact on our fair value measurement:

Simulation Input |  | As of September 30, 2017 |  | At Acquisition February 3, 2017
Adjusted EBITDA Volatility |  | 28.00 | % |  | 29.00 | %
WACC |  | 9.00 | % |  | 10.00 | %
20-year risk free rate |  | 2.63 | % |  | 2.82 | %
Market price of risk |  | 6.18 | % |  | 6.93 | %
Cost of debt |  | 3.94 | % |  | 4.16 | %

The fair value of our investments is estimated using observable market based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs, which consisted of corporate bonds.
The fair value of our Level 2 forward currency contract is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.
The assets related to our Dominican Republic manufacturing facilities are classified as assets held-for-sale. These assets are separately stated in our condensed consolidated balance sheet. The fair value of these Level 3 assets was determined as part of the HIS business valuation and was based on a market approach using comparable building and land sales data and the analysis of market conditions.
There were no transfers between Levels during the three and nine months ended September 30, 2017.
Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):

| Fair value measurements at September 30, 2017
| Total carrying value |  | Quoted prices in active markets for identical assets (level 1) |  | Significant other observable inputs (level 2) |  | Significant unobservable inputs (level 3)
Assets: |  |  |  |  |  |  |
Available for sale securities: |  |  |  |  |  |  |
Short-term | $ | 9,591 |  |  | $ | — |  |  | $ | 9,591 |  |  | $ | — |
Long-term | 15,140 |  |  | — |  |  | 15,140 |  |  | — |
Foreign exchange forwards: |  |  |  |  |  |  |
Prepaid expenses and other current assets | 1,279 |  |  | — |  |  | 1,279 |  |  | — |
Other assets | 309 |  |  | — |  |  | 309 |  |  | — |
Total Assets | $ | 26,319 |  |  | $ | — |  |  | $ | 26,319 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Earn-out liability | $ | 32,000 |  |  | $ | — |  |  | $ | — |  |  | $ | 32,000 |
Total Liabilities | $ | 32,000 |  |  | $ | — |  |  | $ | — |  |  | $ | 32,000 |

17

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Our assets measured at fair value on a nonrecurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):

| Fair value measurements at September 30, 2017 using
| Total carrying value |  | Quoted prices in active markets for identical assets (level 1) |  | Significant other observable inputs (level 2) |  | Significant unobservable inputs (level 3)
Assets: |  |  |  |  |  |  |
Assets held-for-sale | $ | 12,489 |  |  | $ | — |  |  | $ | — |  |  | $ | 12,489 |
Total Assets | $ | 12,489 |  |  | $ | — |  |  | $ | — |  |  | $ | 12,489 |

Note 8: Investment Securities
Our investment securities currently consist of short-term and long-term corporate bonds. Our investment securities are considered available-for-sale and are “investment grade” and carried at fair value. There have been no realized gains or losses on their disposal. Our available-for-sale securities are recorded at amortized cost, which approximates fair value, when material, unrealized gains and losses on available-for-sale securities, net of tax, are included in accumulated other comprehensive loss in the stockholders' equity section of our condensed consolidated balance sheets. The amortized cost of the debt securities are adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in investment income in other income on our condensed consolidated statements of income. The scheduled maturities of the debt securities are between 2018 and 2020. All short-term investment securities are all callable within one year.
Our short and long-term investment securities consisted of the following at September 30, 2017 (in thousands):

| Amortized Cost |  | Unrealized Losses |  | Estimated Fair Value
Short-term corporate bonds | $ | 9,591 |  |  | $ | (16 | ) |  | $ | 9,575 |
Long-term corporate bonds | 15,140 |  |  | (86 | ) |  | 15,054 |
Total investment securities | $ | 24,731 |  |  | $ | (102 | ) |  | $ | 24,629 |

Note 9: Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following (in thousands):

|  | September 30, 2017 |  | December 31, 2016
Third-party receivables due from Pfizer |  | $ | 85,376 |  |  | $ | — |
Prepaid and other expenses - HIS business acquisition related |  | 46,241 |  |  | — |
Prepaid expenses - other |  | 8,633 |  |  | 2,948 |
Prepaid insurance and property taxes |  | 1,401 |  |  | 1,649 |
VAT/GST receivable |  | 3,602 |  |  | 1,018 |
Other |  | 1,218 |  |  | 1,740 |
|  | $ | 146,471 |  |  | $ | 7,355 |

Third-party receivables due from Pfizer relates to trade accounts receivable that has already been collected from customers by Pfizer on our behalf.
18

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 10: Inventories
Inventories consisted of the following (in thousands):

| September 30, 2017 |  | December 31, 2016
Raw material | $ | 74,356 |  |  | $ | 28,435 |
Work in process | 63,970 |  |  | 4,415 |
Finished goods | 182,015 |  |  | 16,414 |
Total inventories | $ | 320,341 |  |  | $ | 49,264 |

During the quarter ended March 31, 2017, we adopted ASU No. 2015-11, accordingly inventories are stated at lower of cost or net realizable value (see Note 2: New Accounting Pronouncements).
Note 11: Property and Equipment
Property and equipment consisted of the following (in thousands):

| September 30, 2017 |  | December 31, 2016
Machinery and equipment | $ | 242,619 |  |  | $ | 96,536 |
Land, building and building improvements | 198,639 |  |  | 63,524 |
Molds | 50,819 |  |  | 39,014 |
Computer equipment and software | 42,002 |  |  | 26,458 |
Furniture and fixtures | 4,174 |  |  | 3,243 |
Construction in progress | 49,788 |  |  | 15,180 |
Total property and equipment, cost | 588,041 |  |  | 243,955 |
Accumulated depreciation | (197,515 | ) |  | (158,259 | )
Property and equipment, net | $ | 390,526 |  |  | $ | 85,696 |

Depreciation expense was $14.0 million and $36.6 million for the three and nine months ended September 30, 2017, respectively, and $4.0 million and $12.3 million for the three and nine months ended September 30, 2016, respectively.
Note 12: Goodwill and Intangible Assets, Net
Goodwill
The following table presents the changes in the carrying amount of our goodwill for 2017 (in thousands):

|  | Total
Balance as of December 31, 2016 |  | $ | 5,577 |
Goodwill acquired |  | 1,015 |
Currency translation |  | 95 |
Balance as of September 30, 2017 |  | $ | 6,687 |

The acquired goodwill relates to our February 1, 2017 acquisition of Fannin (see Note 3: Acquisition, Strategic Transaction and Integration Expenses).
Intangible Assets, Net
Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):
19

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

|  | Weighted Average |  | September 30, 2017
|  | Amortization Life in Years |  | Cost |  | Accumulated Amortization |  | Net
Patents |  | 10 |  | $ | 16,603 |  |  | $ | 10,699 |  |  | $ | 5,904 |
Customer contracts |  | 10 |  | 11,406 |  |  | 4,797 |  |  | 6,609 |
Non-contractual customer relationships |  | 9 |  | 55,080 |  |  | 4,944 |  |  | 50,136 |
Trademarks |  | 4 |  | 425 |  |  | 425 |  |  | — |
Trade name |  | 15 |  | 7,310 |  |  | 975 |  |  | 6,335 |
Developed technology |  | 11 |  | 81,801 |  |  | 5,654 |  |  | 76,147 |
Total definite-lived intangible assets |  |  |  | $ | 172,625 |  |  | $ | 27,494 |  |  | $ | 145,131 |
Indefinite-lived IPR&D |  |  |  | 7,207 |  |  | — |  |  | 7,207 |
Total intangible assets |  |  |  | $ | 179,832 |  |  | $ | 27,494 |  |  | $ | 152,338 |

|  | Weighted Average |  | December 31, 2016
|  | Amortization Life in Years |  | Cost |  | Accumulated Amortization |  | Net
Patents |  | 10 |  | $ | 14,423 |  |  | $ | 9,326 |  |  | $ | 5,097 |
MCDA contract * |  | 10 |  | 8,571 |  |  | 8,571 |  |  | — |
Customer contracts |  | 9 |  | 5,319 |  |  | 4,512 |  |  | 807 |
Non-contractual customer relationships |  | 15 |  | 7,080 |  |  | 590 |  |  | 6,490 |
Trademarks |  | 4 |  | 425 |  |  | 425 |  |  | — |
Trade name |  | 15 |  | 7,310 |  |  | 609 |  |  | 6,701 |
Developed technology |  | 10 |  | 3,797 |  |  | 509 |  |  | 3,288 |
Total |  |  |  | $ | 46,925 |  |  | $ | 24,542 |  |  | $ | 22,383 |

*MCDA contract: Manufacturing, Commercialization and Development Agreement with Hospira, Inc., dated May 1, 2005 (the "MCDA”). The MCDA was terminated in connection with the acquisition of the HIS business on February 3, 2017.
Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives. During the three and nine months ended September 30, 2017, intangible asset amortization expense was $3.6 million and $10.9 million, respectively, as compared to $0.7 million and $2.1 million during the three and nine months ended September 30, 2016, respectively.
As of September 30, 2017 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):

Remainder of 2017 |  | $ | 4,218 |
2018 |  | 16,353 |
2019 |  | 15,938 |
2020 |  | 15,798 |
2021 |  | 15,716 |
Thereafter |  | 77,108 |
Total |  | $ | 145,131 |

20

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 13: Accrued Liabilities and Other Long-term Liabilities
Accrued liabilities consist of the following (in thousands):

|  | September 30, 2017 |  | December 31, 2016
Salaries and benefits |  | $ | 50,964 |  |  | $ | 5,702 |
Incentive compensation |  | 26,014 |  |  | 7,912 |
Accrued product field action |  | 15,225 |  |  | — |
Third-party inventory |  | 3,008 |  |  | — |
Sales taxes |  | 339 |  |  | 1,472 |
Restructuring accrual |  | 3,002 |  |  | 423 |
Accrued insurance |  | 3,857 |  |  | — |
Deferred revenue |  | 5,937 |  |  | 18 |
Accrued professional fees |  | 8,945 |  |  | — |
Legal accrual |  | 2,567 |  |  | 4,177 |
Accrued marketing |  | 2,125 |  |  | — |
Outside commissions |  | 2,822 |  |  | 1,141 |
Warranties and returns |  | 1,335 |  |  | — |
Acquisition-related accrual |  | — |  |  | 2,750 |
Other |  | 20,007 |  |  | 2,301 |
|  | $ | 146,147 |  |  | $ | 25,896 |

Other long-term liabilities consist of the following (in thousands):

|  | September 30, 2017 |  | December 31, 2016
Contract liabilities |  | $ | 54,642 |  |  | $ | — |
Deferred revenue |  | 5,787 |  |  | — |
Benefits |  | 3,738 |  |  | 1,107 |
Product liability |  | 3,102 |  |  | — |
Other |  | 765 |  |  | — |
|  | $ | 68,034 |  |  | $ | 1,107 |

Note 14: Income Taxes
Income taxes were accrued at an estimated effective tax rate of (66)% and 25% for the nine months ended September 30, 2017 and 2016, respectively. Those rates differ from that computed at the federal statutory rate of 35%.
The effective tax rate for the nine months ended September 30, 2017 differs from the federal statutory rate of 35% principally because of the effect the mix of U.S. and foreign incomes, state income taxes, tax credits and the impact of the gain on bargain purchase. The effective tax rate during the nine months ended September 30, 2017 also included a material tax benefit of $12.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate.
The effective tax rate for the nine months ended September 30, 2016 differs from the federal statutory rate of 35% principally because of the effect of foreign and state income taxes, tax credits and deductions for domestic production activities. The effective tax rate during the nine months ended September 30, 2016 also included a material tax benefit of $6.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate.
21

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 15: Long-Term Obligations
3-Year Interest-Only Senior Note
On February 3, 2017, we partially funded the acquisition of the HIS business from Pfizer with a $75 million Seller Note issued by Pfizer (the "Senior Note") contemporaneous with the acquisition. The Senior Note will mature on February 3, 2020.
Long-term obligations consisted of the following at September 30, 2017 (in thousands):

| September 30, 2017
Senior Note matures in 2020, variable interest rate | $ | 75,000 |
Less: current portion of long-term obligations | — |
Long-term obligations, net | $ | 75,000 |

Principal payments
As of September 30, 2017, aggregate future principal payments for long-term obligations (including any current portion of long-term debt) were as follows (in thousands):

Years Ending |  |
2017 |  | $ | — |
2018 |  | — |
2019 |  | — |
2020 |  | 75,000 |
Thereafter |  | — |
Total |  | $ | 75,000 |

The Senior Note is not subject to any required principal payments prior to the maturity date. We may, at our option, upon notice prepay without penalty at any time all, or from time to time any part of, this senior note at 100% of the principal amount, plus accrued but unpaid interest through the repayment date.
Interest rate
Interest on the Senior Note is variable and will accrue at LIBOR plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter. Interest is to be paid every three months following the February 3, 2017 effective date of the Senior Note.
Guarantors
Our obligations under the Senior Note are unconditionally guaranteed by each of our existing and subsequently acquired or formed wholly-owned domestic subsidiaries, subject to certain exclusions.
Debt Covenants
The Senior Note has restrictions, beginning on the effective date and thereafter, pertaining to limitations on debt, liens, loans, advances, acquisitions, other investments, dividends, redemptions, repurchases of equity interests, fundamental changes in the line of business, dispositions, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business and accounting changes or change in fiscal year.
22

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 16: Stockholders' Equity
Common Stock
On February 3, 2017, we acquired the HIS business from Pfizer and as partial consideration, we issued 3.2 million unregistered shares of our common stock to Pfizer. The fair value of the common stock was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period, whereby Pfizer is prohibited from the transfer of the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement (see Note 18: Collaborative and Other Arrangements) or (ii) eighteen months.
Treasury Stock
In July 2010, our Board of Directors approved a common stock purchase plan to purchase up to $40.0 million of our common stock. This plan has no expiration date. During the three and nine months ended September 30, 2017, we did not purchase any shares of our common stock under the stock purchase plan. As of September 30, 2017, the remaining authorized amount under this purchase plan is approximately $7.2 million. We are currently limited on share purchases in accordance with the terms and conditions of our Senior Note with Pfizer, (see Note 15: Long-Term Obligations).
For the nine months ended September 30, 2017, we withheld 27,129 shares of our common stock from employee vested restricted stock units in consideration for $4.0 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases.
Accumulated Other Comprehensive Income (Loss)
The components of AOCI, net of tax, were as follows (in thousands):

|  | Foreign Currency Translation Adjustments |  | Unrealized Gains on Cash Flow Hedges | Other Adjustments |  | Total
Balance as of December 31, 2016 |  | $ | (21,272 | ) |  | $ | — |  | $ | — |  |  | $ | (21,272 | )
Other comprehensive income (loss) before reclassifications |  | 16,747 |  |  | 1,329 |  | (238 | ) |  | 17,838 |
Amounts reclassified from AOCI |  | — |  |  | (344 | ) | — |  |  | (344 | )
Other comprehensive income (loss) |  | 16,747 |  |  | 985 |  | (238 | ) |  | 17,494 |
Balance as of September 30, 2017 |  | $ | (4,525 | ) |  | $ | 985 |  | $ | (238 | ) |  | $ | (3,778 | )

Note 17: Commitments and Contingencies
Legal Proceedings
Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that the defendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS Purchase Agreement.
In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira, Inc. requesting that the company provide information regarding certain business practices in the intravenous solutions part of the HIS business.
23

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Separately, in April 2017, we received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoena calls for production of documents related to the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is the subject of cross-claims for indemnification by both us and Pfizer under the HIS Purchase Agreement. We will coordinate with Pfizer to produce records to the New York Attorney General and the Department of Justice.
From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.
Off Balance Sheet Arrangements
In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters or other matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.
Contingencies
We have a contractual earn-out arrangement in connection with our acquisition of the HIS business, whereby Pfizer may be entitled up to an additional $225 million in cash upon achievement of performance targets for the company for the three years ending December 31, 2019, see (Note 3: Acquisition, Strategic Transaction and Integration Expenses). The amount to be paid cannot be determined until the earn-out period has expired.
Commitments
As part of the HIS business acquisition, we assumed a number of non-cancellable operating office and industrial leases. Rental expense under operating lease agreements was $2.3 million and $5.3 million for the three and nine months ended September 30, 2017, respectively, and $0.2 million and $0.4 million for the three and nine months ended September 30, 2016, respectively.
We also entered into the Senior Note with Pfizer to partially fund the HIS business acquisition (see Note 15: Long-Term Obligations).
The following table summarizes our principal contractual commitments, excluding open orders for purchases that support normal operations, as of September 30, 2017 (in thousands):

| Payments Due By Period
| Total |  | Remainder of 2017 |  | 2018 |  | 2019 |  | 2020 |  | 2021 |  | Thereafter
Long-term debt obligations | $ | 75,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 75,000 |  |  | $ | — |  |  | $ | — |
Interest payments on long-term debt obligations | 7,475 |  |  | 763 |  |  | 3,198 |  |  | 3,215 |  |  | 299 |  |  | — |  |  | — |
Operating lease obligations | 33,763 |  |  | 2,638 |  |  | 9,208 |  |  | 5,769 |  |  | 3,378 |  |  | 3,219 |  |  | 9,551 |
Purchase obligations(1) | 97,970 |  |  | 5,513 |  |  | 4,477 |  |  | 14,005 |  |  | 34,757 |  |  | 39,218 |  |  | — |
Total contractual obligations | $ | 214,208 |  |  | $ | 8,914 |  |  | $ | 16,883 |  |  | $ | 22,989 |  |  | $ | 113,434 |  |  | $ | 42,437 |  |  | $ | 9,551 |

___________________________________
(1) Purchase obligations includes agreements to purchase goods that are enforceable and legally binding. These amounts are not accrued as of September 30, 2017.
24

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 18: Collaborative and Other Arrangements
On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSA's"), (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSA's provide each party with mutually beneficial interests and both of the MSA's are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products.
On February 3, 2017, as part of the HIS business acquisition, we entered into an agreement with Pfizer, whereby Pfizer will provide certain transitional services to us for finance, business technology, regulatory, human resources, global operations, procurement, quality and global commercial operation services ("Enabling Function Services"). We pay a monthly service fee for each service provided, and share equally with Pfizer in certain set-up costs and, as applicable, service exit costs. Our share of the set-up costs and service exit costs, in the aggregate, are not to exceed $22.0 million. The service fees are subject to a fee cap of (i) $62.5 million during the initial twelve month period and (ii) $31.3 million during the subsequent six month period. Only the Enabling Function Services are subject to the fee cap, any services provided after expiration of the agreement or services that are not Enabling Function Services may result in service fees outside the fee cap. The service fees are intended to reasonably approximate Pfizer’s cost of providing the Enabling Function Services. We may terminate, in whole only, any particular service and the fee cap would be reduced proportionate to the services terminated. Partial reduction in the provision of any specific service may be made but only with the prior written consent of Pfizer.
On February 3, 2017, as part of the HIS business acquisition, we also entered into a reverse transitional services agreement, where we will provide to Pfizer certain transitional services ranging in term from three to eighteen months. Services include support for real estate, research and development, infrastructure, logistics, quality, site operations, safety, commercial and finance, and regulatory support services.
Note 19: Subsequent Events
On November 8, 2017, we entered into a new five-year Senior Secured Revolving Credit Facility ("Credit Facility") with various lenders for $150 million, with Wells Fargo Bank, N.A. as the administrative agent. The Credit Facility has an accordion feature that would enable us to increase the borrowing capacity of the credit facility by the greater of (i) $100 million and (ii) 2.00x Total Leverage. Under the terms of the facility we will be subject to certain financial covenants pertaining to leverage and fixed charge coverage ratios. Borrowings under the Credit Facility will bear interest at LIBOR plus an applicable margin tied to the leverage ratio in effect. The unused portion of the Credit Facility will be subject to a per annum commitment fee which is also calculated using the leverage ratio in effect.
On November 8, 2017, we fully repaid the $75 million in outstanding principal under the senior note payable to Pfizer.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following information should be read in conjunction with the condensed consolidated financial statements and accompanying notes in this Form 10-Q, as well as the audited consolidated financial statements and related notes for the fiscal year ended December 31, 2016 included in our Annual Report on Form 10-K.
When used in this report, the terms “we,” “us,” and “our” refer to ICU Medical, Inc ("ICU") and its subsidiaries included in our condensed consolidated financial statements unless context requires otherwise.
Overview
Our Business After the Hospira Infusion Systems Acquisition
On February 3, 2017, we completed the acquisition of Pfizer Inc.'s ("Pfizer") Hospira Infusion Systems ("HIS") business. See "Acquisitions" below for additional detail regarding the acquisition. HIS was a leading global provider of intravenous ("IV") infusion therapy products to hospitals and alternate site providers, such as clinics, home health care providers and long-term care facilities. Our acquisition of the HIS business was strategic and provides us with an increase in scale and product portfolio that we believe will result in a stronger competitive position within the industry. We believe the
25

Table of Contents
HIS business acquisition was the natural evolution for us based on a long-term successful and productive partnership with HIS for over 20 years.
As a result of the HIS business acquisition, we are one of the world's leading pure-play infusion therapy companies with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. In addition, we manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients.
The following information is in addition to and not a substitute for the Business section under Part 1, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2016 and should be read in conjunction with that filing.
Manufacturing Changes
With the acquisition of the HIS business, we now operate an infusion pump and dedicated set manufacturing plant in La Aurora de Heredia, Costa Rica, which manufactures key products that include large volume pumps ("LVP"), patient-controlled analgesia ("PCA") pumps (among others, the Plum™ and LifeCare PCA™), and consumable infusion products. The Sapphire™ family of pumps are manufactured by Q Core Medical, Ltd. We also operate manufacturing facilities in San Cristobal, Dominican Republic, which has key products that include consumable infusion sets and other IV accessories. We are in the process of closing the Dominican Republic facilities and transferring assets and production to Costa Rica and to our plant in Ensenada, Mexico.
We manufacture infusion therapy solutions products in Austin, Texas.
In addition, we have four main regional device service centers in San Jose, California; Sligo, Ireland; San Laurent, Quebec, Canada; and Botany, Australia.
On February 3, 2017, as part of our HIS business acquisition, we also entered into two Manufacturing and Supply Agreements ("MSAs") under which, (i) Pfizer manufactures and supplies us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, with a one-time two-year option to extend. The initial supply price will be annually updated and is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products.
Distribution Changes
The U.S. distribution of solutions, IV sets and accessories is supported by a network of three owned distribution centers acquired in the HIS business acquisition, which include King of Prussia, Pennsylvania; Los Angeles, California; and Dallas, Texas. We also assumed a number of agreements with third-party public warehouse providers.
We also acquired as part of the HIS business a private fleet of tractors and trailers operated by contracted drivers that provide both over the road and local route needs.
Internationally, we manage our operations through the Netherlands, which utilizes international regional hubs and we also manage operations through independent distributors.
Government Regulation Changes
The acquisition of our solutions product-line and the entry into new global markets subjects us to additional government regulation across multiple jurisdictions.
Drug Regulation in the U.S.
In the United States, IV solutions are considered pharmaceutical products and subject to extensive pre- and post-market regulations by the Food and Drug Administration ("FDA"), including the research, development, testing, manufacturing, approval, labeling, storage, record keeping, advertising, promotion and marketing, distribution, post approval monitoring and reporting and import and export of drugs to assure the safety and effectiveness of medical products for their intended use.
26

Table of Contents
The pre-market approval process is a time-intensive multi-phased process. When successfully completed an application may be submitted to the FDA that includes detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things. This application process may be subject to substantial fees.
FDA approval is typically required before any new drug can be marketed. A New Drug Application ("NDA"), or an Abbreviated New Drug Application ("ANDA"), is typically required to be submitted to the FDA to obtain approval of pharmaceutical products.
Before approval, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, the FDA may inspect one or more clinical trial sites to assure compliance with good clinical practice, or GCP, requirements.
Even after a drug or device has been approved by the FDA for sale, the FDA may require that certain post-approval requirements be satisfied, including the conduct of additional clinical studies. If such post-approval conditions are not satisfied, the FDA may withdraw its approval of the drug. After the FDA permits a drug to enter commercial distribution, numerous regulatory requirements continue to apply. The production, distribution, and post market activities are subject to the FDA current Good Manufacturing Practices ("cGMP") requirements. FDA will typically conduct inspections of the manufacturing facilities.
Device Regulations in Various Markets.
In the United States, unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the Federal Food, Drug and Cosmetic Act ("FDC Act") also referred to as a 510(k) clearance, or approval from the FDA of a pre-market approval ("PMA") application. Both the 510(k) clearance and PMA processes can be expensive, and lengthy, and require payment of significant user fees, unless an exemption is available.
FDA device regulations include device design, production, distribution and post market activities. To market the devices in Canada, Australia, the European Union, and other regions, devices typically are subject to the product registrations, licenses and certification requirements.
Device facilities are typically inspected by the FDA and other international regulatory agencies and notified bodies.
Competition Changes
With the acquisition of the HIS business we have entered into the infusion pump and solutions market. The market for infusion therapy products in general is intensely competitive. The competitive environment for IV smart pumps is no different with market share measured based on installed base. We will be able to leverage the HIS business' existing installed base; however we face strong competitors in the U.S. including Becton Dickinson ("BD"), Baxter International, Inc. ("Baxter") and B. Braun Medical, Inc. ("B. Braun"). Internationally, we face equally strong competitors in the pump market including Fresenius Kabi a division of Fresenius Group ("Fresenius"), B. Braun Melsungen AG ("B. Braun AG") and Smiths Medical. These competitors benefit from a wider breadth and depth of their product offerings and greater financial, research and development and marketing resources than we have. The smart pump market in recent years has been troubled with security concerns, and product recalls. We believe our ability to effectively compete in this market will be determined by our ability to build our brand strength using the development of technological advancements aimed at increasing the quality, reliability and safety of our pumps while at the same time focusing on manufacturing efficiency and cost-effectiveness, which are operationally challenging with evolving product lines.
The solutions market is also competitive, although we believe it is more difficult for new competitors to enter because it is a highly regulated business requiring expertise and stable manufacturing capabilities. Our competitors include Baxter, B. Braun and Fresenius. Demand for IV solutions is typically high and raw materials required to produce IV solutions are readily available. Our ability to compete will depend on our ability to maximize production, develop innovations in our product line, focus on cost-effectiveness and our ability to maintain the appropriate quality infrastructure.
We believe the breadth of the HIS business product portfolio has increased our competitiveness as we can now provide a one-stop shop for customers and offer more flexible competitive pricing using contract bundling. We believe the infusion
27

Table of Contents
pump will also enable us to pull through a larger volume of higher margin consumables, such as IV sets, accessories and solutions. In addition, we are now a vertically integrated supplier, which allows us greater access to a unified distribution channel.
Patent Changes
As part of the HIS business acquisition, we acquired rights, title and interest to a substantial number of patents and patent applications and related provisionals, divisionals, continuations, continuations-in-part, reissues, reexaminations, extensions, and substitutions of any of the foregoing (“Patent Rights”), that were primarily used or held for use by Pfizer in the HIS business. There is however, no single patent or group of patents that we acquired that we believe is material in relation to our business as a whole.
Employee Changes
The HIS business acquisition had a significant impact on our number of employees. At September 30, 2017, we employed approximately 7,000 people across our global operations, with approximately 2,700 employed in the United States.
Market Segments
We have restructured our market segments to integrate the HIS business product portfolio and have presented our financial results in accordance with the following four market segments with our primary products listed:
Infusion Consumables
Infusion Therapy

• | Clave® needlefree products, including the MicroClave, MicroClave Clear, and NanoClave brand of connectors, accessories, extension and administration sets used for the administration of IV fluids and medications. Custom infusion sets are a subset of the Clave product category, and designed to meet specialized infusion therapy practice in areas such as anesthesia and pediatrics.

• | Neutron® Catheter Patency Connector, used to help maintain patency of central venous catheters.

• | SwabCap® Disinfecting Cap, used to protect and disinfect any needlefree connector including, including competitive brands of connectors.

• | Custom infusion sets

• | Tego® Hemodialysis Connector

• | NovaCath® and SuperCath® Peripheral IV Catheters

Oncology Pharmacy Devices and Consumables

• | ChemoLock® Closed System Transfer Device (CSTD) is a Pharmacy preferred CSTD used for the preparation and administration of hazardous drugs.

• | ChemoClave® Closed System Transfer Device (CSTD) is an ISO standard and universally compatible CSTD used for the preparation and administration of hazardous drugs.

• | Diana™ hazardous drug compounding system, used for the preparation of hazardous drugs.

IV Solutions

• | Sterile Solutions - IV solutions, normal saline, Ringers etc. is used to replenish fluids and electrolytes by IV infusion.

28

Table of Contents

• | Irrigation Solutions - Used externally on open wounds to hydrate the wound, remove deep debris, assist with visual examination, to prevent infection and improve healing.

• | Nutritionals - Solutions that feed vitamins, minerals and other natural therapeutic substances directly into the blood stream. We are committed to helping our customers deliver more comprehensive patient-care therapies, delivering an extensive source of nutrients for patients who cannot consume a normal diet.

Infusion Systems
Infusion Pump Hardware - Our current pump platform includes four infusion pumps:

▪ | Plum 360™: The Plum 360™ infusion pump is a ICU Medical MedNet™ ready large volume infusion pump with an extensive drug library and wireless capability.

▪ | LifeCare PCA™: The LifeCare PCA™ infusion pump is a ICU Medical MedNet™ ready patient-controlled analgesia pump.

▪ | SapphirePlus™: The SapphirePlus™ infusion pump is a ICU Medical MedNet™ ready large volume infusion pump with an extensive drug library and wireless capability.

▪ | Sapphire™: The Sapphire™ infusion pump is a compact infusion system used in ambulatory and hospital settings. The Sapphire™ infusion pump comes in multi-therapy and epidural-only configurations.

We offer the ICU Medical MedNet™ safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to help prevent medication errors.
Critical Care

• | Hemodynamic Monitoring Systems

• | Cogent® 2-in-1 Hemodynamic Monitoring System

• | LiDCO LX1 TM Noninvasive Hemodynamic Monitoring System

• | CardioFlo® Hemodynamic Monitoring Sensor

• | TriOx® PICC Minimally Invasive Venous Oximetry Sensor

• | SafeSet® Closed Blood Sampling and Conservation System

• | Transpac® Consumable Blood Pressure Transducers

• | Other Critical Care Products and Accessories

Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as clinics, home health care providers and long-term care facilities.
The following table summarizes our total worldwide revenue by domestic and international markets by amount and as a percentage of total revenue (in millions, except percentages):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
| $ |  | % of Revenue |  | $ |  | % of Revenue |  | $ |  | % of Revenue |  | $ |  | % of Revenue
Domestic | $ | 262.2 |  |  | 76 | % |  | $ | 66.8 |  |  | 69 | % |  | $ | 690.1 |  |  | 75 | % |  | $ | 198.1 |  |  | 70 | %
International | 81.0 |  |  | 24 | % |  | 30.3 |  |  | 31 | % |  | 232.4 |  |  | 25 | % |  | 85.6 |  |  | 30 | %
Total Revenue | $ | 343.2 |  |  | 100 | % |  | $ | 97.1 |  |  | 100 | % |  | $ | 922.5 |  |  | 100 | % |  | $ | 283.7 |  |  | 100 | %

29

Table of Contents
The following table sets forth, for the periods indicated, total revenue by market segment as a percentage of total revenue:

|  | Three months ended September 30, |  | Nine Months Ended September 30,
Product line |  | 2017 |  | 2016 |  | 2017 |  | 2016
Infusion Consumables |  | 27 | % |  | 86 | % |  | 27 | % |  | 86 | %
IV Solutions |  | 42 | % |  | — | % |  | 41 | % |  | — | %
Infusion Systems |  | 24 | % |  | — | % |  | 22 | % |  | — | %
Critical Care |  | 4 | % |  | 14 | % |  | 4 | % |  | 14 | %
Other |  | 3 | % |  | — | % |  | 6 | % |  | — | %
|  | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %

We manage our product distribution in the U.S. through a network of three owned distribution facilities, as well as, through direct channels, which include independent distributors and the end users of our products, and as original equipment manufacturer suppliers. Most of our independent distributors handle the full line of our products. Internationally, we manage our operations through the Netherlands, which utilizes international regional hubs and we also manage our operations through independent distributors.
A substantial amount of our products are sold to group purchasing organization ("GPO") member hospitals. We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships to secure long-term contracts with large healthcare providers and major buying organizations. As a result of this marketing and distribution strategy we derive most of our revenue from a relatively small number of distributors and manufacturers. Although we believe that we are not dependent on any single distributor for distribution of our products, the loss of a strategic relationship with a customer or a decline in demand for manufacturing customers' products could have a material adverse effect on our operating results.
We believe that achievement of our growth objectives worldwide will require increased efforts by us in sales and marketing and product acquisition and development; however, there is no assurance that we will be successful in implementing our growth strategy. Product development or acquisition efforts may not succeed, and even if we do develop or acquire additional products, there is no assurance that we will achieve profitable sales of such products. Increased expenditures for sales and marketing and product acquisition and development may not yield desired results when expected, or at all. While we have taken steps to control these risks, there are certain risks that may be outside of our control, and there is no assurance that steps we have taken will succeed.
Acquisitions
On February 1, 2017, we acquired 100% interest in Fannin (UK) Limited ("Fannin") for total consideration of approximately $1.5 million. Fannin provides infusion therapy consumable products to the healthcare sector in the United Kingdom and Ireland.
On February 3, 2017, we acquired 100% interest in Pfizer's HIS business for total consideration of approximately $260.0 million in cash (net of estimated working capital adjustments paid at closing) and the issuance of 3.2 million shares of our common stock. We partially funded the cash portion of the consideration paid with a $75 million three-year interest-only seller note. The fair value of the common shares issued to Pfizer was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period whereby Pfizer cannot transfer the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement or (ii) eighteen months.
30

Table of Contents
Consolidated Results of Operations
We present income statement data in Part I, Item 1 - Financial Statements. The following table shows, for the three and nine months ended September 30, 2017 and 2016, respectively, the percentages of each income statement caption in relation to total revenue:

|  | Three months ended September 30, |  | Nine Months Ended September 30,
|  | 2017 |  | 2016 |  | 2017 |  | 2016
Total revenue |  | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %
Gross margin |  | 33 | % |  | 53 | % |  | 31 | % |  | 53 | %
Selling, general and administrative expenses |  | 22 | % |  | 23 | % |  | 25 | % |  | 24 | %
Research and development expenses |  | 4 | % |  | 4 | % |  | 4 | % |  | 3 | %
Restructuring and strategic transaction |  | 5 | % |  | 3 | % |  | 7 | % |  | 2 | %
Change in fair value of earn-out |  | 2 | % |  | — | % |  | 1 | % |  | — | %
Total operating expenses |  | 33 | % |  | 30 | % |  | 37 | % |  | 29 | %
(Loss) income from operations |  | — | % |  | 23 | % |  | (6 | )% |  | 24 | %
Bargain purchase gain |  | 2 | % |  | — | % |  | 8 | % |  | 1 | %
Interest expense |  | — | % |  | — | % |  | — | % |  | — | %
Other income, net |  | — | % |  | — | % |  | — | % |  | — | %
Income before income taxes |  | 2 | % |  | 23 | % |  | 2 | % |  | 25 | %
Provision (Benefit) for income taxes |  | 1 | % |  | 4 | % |  | (1 | )% |  | 6 | %
Net income |  | 1 | % |  | 19 | % |  | 3 | % |  | 19 | %

Infusion Consumables
The following table summarizes our total Infusion Consumables revenue (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
Infusion Consumables | $ | 92.7 |  |  | $ | 82.8 |  |  | $ | 9.9 |  |  | 12.0 | % |  | $ | 245.9 |  |  | $ | 242.7 |  |  | $ | 3.2 |  |  | 1.3 | %

The Infusion Consumables revenue included our acquired revenue from the HIS business, which year-to-date includes approximately eight months of revenue from the point of closing of the transaction to the end of the current quarter. Additionally, the Infusion Consumables market segment includes our legacy Infusion Therapy and Oncology businesses.
IV Solutions
The following table summarizes our total IV Solutions revenue (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
IV Solutions | $ | 143.7 |  |  | $ | — |  |  | $ | 143.7 |  |  | — |  | $ | 375.5 |  |  | $ | — |  |  | $ | 375.5 |  |  | —

31

Table of Contents
The IV Solutions revenue is a result of the acquisition of the HIS business. For the three and nine months ended September 30, 2017, IV Solutions revenue included $16.2 million and $51.9 million, respectively, in contract manufacturing to Pfizer at cost in accordance with our MSA agreement. The year-to-date revenue represents approximately eight months of revenue from the point of closing of the transaction to the end of the current quarter.
Infusion Systems
The following table summarizes our total Infusion Systems revenue (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
Infusion Systems | $ | 82.8 |  |  | $ | — |  |  | $ | 82.8 |  |  | — |  | $ | 202.6 |  |  | $ | — |  |  | $ | 202.6 |  |  | —

The Infusion Systems revenue is a result of the acquisition of the HIS business. The year-to-date revenue represents approximately eight months of revenue from the point of closing of the transaction to the end of the current quarter.
Critical Care
The following table summarizes our total Critical Care revenue (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
Critical Care | $ | 12.9 |  |  | $ | 14.0 |  |  | $ | (1.1 | ) |  | (7.9 | )% |  | $ | 37.2 |  |  | $ | 40.3 |  |  | $ | (3.1 | ) |  | (7.7 | )%

Critical care revenue was essentially flat as compared to the same periods in the prior year.
Other Revenue
For the three and nine months ended September 30, 2017, other revenue was $0.2 million and $0.9 million, respectively. As part of the HIS business acquisition, the closing of certain foreign jurisdictions were deferred, as such, we entered into a Net Economic Benefit agreement with Pfizer (see Note 3: Acquisition, Strategic Transaction and Integration Expenses in our accompanying condensed consolidated financial statements for additional information). The revenue data related to these deferred closing entities is not available by market segment, therefore our other revenue below includes amounts related to these entities and differs from the amounts reported as other revenue on our condensed consolidated statements of operations.
32

Table of Contents
The following table summarizes our total Other Revenue (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
Other Revenue | $ | 11.1 |  |  | $ | 0.3 |  |  | $ | 10.8 |  |  | 3,600.0 | % |  | $ | 61.3 |  |  | $ | 0.7 |  |  | $ | 60.6 |  |  | 8,657.1 | %

Gross Margins
For the three and nine months ended September 30, 2017, gross margins were 32.5% and 31.3%, respectively, as compared to 52.8% and 53.1% for the three and nine months ended September 30, 2016, respectively. The decrease in gross margin for the three and nine months ended September 30, 2017, as compared to the same periods in the prior year is due to the integration of HIS, which has historically lower gross margins than our legacy business. Additionally, there was an impact of approximately four and seven percentage points for the three and nine months ended September 30, 2017, respectively, related to the step-up of inventory from our purchase accounting and also a temporary negative impact on absorption due to our planned inventory reduction.
Selling, General and Administrative (“SG&A”) Expenses
The following table summarizes our total SG&A Expenses (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
SG&A | $ | 76.8 |  |  | $ | 22.4 |  |  | $ | 54.4 |  |  | 242.9 | % |  | $ | 226.8 |  |  | $ | 66.8 |  |  | $ | 160.0 |  |  | 239.5 | %

SG&A expenses increased for the three months ended September 30, 2017, as compared to the same period in the prior year, primarily due to the impact of the HIS acquisition. Accounting and information technology fees increased $20.1 million, compensation increased $15.6 million, depreciation expense increased $3.7 million, computer hardware and software increased $2.3 million, travel and related expenses increased $1.8 million. Accounting and information technology fees increased due to the expenses incurred under the transition services agreement with Pfizer. Compensation increased due to an increase in headcount related to the HIS acquisition, and from new employees hired to support the company post-acquisition. Depreciation expense increased due to the depreciation of the HIS assets acquired. Travel and related expenses increased primarily due to the integration of the HIS acquisition and the post-acquisition operational activity. Computer hardware and software increases were due to the post-acquisition needs to stand up the company.
SG&A expenses increased for the nine months ended September 30, 2017, as compared to the same period in the prior year, primarily due to the impact of the HIS acquisition. Accounting and information technology fees increased $54.2 million, compensation increased $57.1 million, depreciation expense increased $9.4 million, travel and related expenses increased $3.9 million, commissions increased $3.4 million and computer hardware and software increased $2.8 million. See above SG&A variance explanations related to the three months ended September 30, 2017, as compared to the same period in the prior year, as they are also relevant explanations for the above SG&A variances for the nine months ended September 30, 2017, as compared to the same period in the prior year. Commissions increased due to the increase in revenue.
Research and Development (“R&D”) Expenses
The following table summarizes our total R&D Expenses (in millions):

| Three months ended September 30, |  | Nine Months Ended September 30,
| 2017 |  | 2016 |  | $ Change |  | % Change |  | 2017 |  | 2016 |  | $ Change |  | % Change
R&D | $ | 12.8 |  |  | $ | 3.7 |  |  | $ | 9.1 |  |  | 245.9 | % |  | $ | 37.4 |  |  | $ | 10.3 |  |  | $ | 27.1 |  |  | 263.1 | %

R&D expenses increased for the three and nine months ended September 30, 2017, as compared to the same periods in the prior year due to the acquisition of HIS.
33

Table of Contents
Restructuring and Strategic Transaction and Integration Expenses
Restructuring and strategic transaction and integration expenses were $18.7 million and $68.0 million for the three and nine months ended September 30, 2017, respectively, as compared to $2.8 million and $4.3 million for the three and nine months ended September 30, 2016, respectively.
Restructuring charges
Restructuring charges were $3.2 million and $19.0 million for the three and nine months ended September 30, 2017, respectively. These charges were related to (i) severance costs from the reduction in our workforce needed to eliminate duplicative positions created as a result of the HIS acquisition and (ii) we are also in the process of closing our Dominican Republic manufacturing facilities and have incurred expenses associated with the closure and transfer of assets and production to our Costa Rica and Mexico manufacturing facilities. We expect to pay unpaid restructuring charges as of September 30, 2017, by the end of the end of 2017.
Restructuring charges were $0.4 million and $0.8 million for the three and nine months ended September 30, 2016, respectively. These charges were primarily related to residual expenses for the closure of our Slovakian manufacturing facility and we incurred $0.2 million related to other restructuring activities.
Strategic transaction and integration expenses
Strategic transaction and integration expenses were $15.5 million and $49.0 million for the three and nine months ended September 30, 2017, respectively, primarily related to our acquisition of the HIS business.
Strategic transaction and integration expenses were $2.4 million and $3.5 million for the three and nine months ended September 30, 2016, related to initial costs incurred on our acquisition of HIS, to our 2015 acquisition of EXC Holding Corp. and to our second quarter 2016 acquisition of Tangent Medical Technologies, Inc.
Change in Fair Value of Earn-out
The fair value revaluation of our earn-out resulted in a loss of $7.0 million and $13.0 million for the three and nine months ended September 30, 2017.
Bargain Purchase Gain
The HIS acquisition resulted in a bargain purchase gain. For the three and nine months ended September 30, 2017 we recognized a bargain purchase gain of $8.5 million and $71.8 million, respectively, related to this acquisition. The bargain purchase gain represents the excess of the estimated fair market value of the identifiable tangible and intangible assets acquired and liabilities assumed, net of deferred tax liabilities over the total purchase consideration. The bargain purchase gain is subject to additional adjustment upon the finalization of the valuations of acquired assets and liabilities associated with the HIS acquisition.
Interest Expense
Interest expense was $0.7 million and $1.7 million for the three and nine months ended September 30, 2017, respectively. The interest expense is related to the $75 million seller note from Pfizer as part of the HIS business acquisition. This three-year interest only seller note bears interest at LIBOR plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter.
Other (Expense) Income
Other (expense) income was $0.6 million and $(2.0) million for the three and nine months ended September 30, 2017, respectively. Other (expense) income was $0.3 million and $0.6 million for the three and nine months ended September 30, 2016, respectively.
34

Table of Contents
Income Taxes
Income taxes were accrued at an estimated effective tax rate of (66)% and 25% for the nine months ended September 30, 2017, and 2016, respectively.
The effective tax rate for the nine months ended September 30, 2017 differs from the federal statutory rate of 35% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, tax credits and the impact of the gain on bargain purchase. The effective tax rate during the nine months ended September 30, 2017 also included a material tax benefit of $12.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate.
The effective tax rate for the nine months ended September 30, 2016 differs from the federal statutory rate of 35% principally because of the effect of foreign and state income taxes, tax credits and deductions for domestic production activities. The effective tax rate during the nine months ended September 30, 2016 also included a material tax benefit of $6.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate.
Liquidity and Capital Resources
During the first nine months of 2017, our cash, cash equivalents and short and long-term investments decreased by $119.7 million from $445.1 million at December 31, 2016 to $325.3 million at September 30, 2017.
Cash Flows from Operating Activities
Our net cash provided by operations for the nine months ended September 30, 2017 was $69.9 million. Net income plus adjustments for non-cash net expenses contributed $31.5 million to cash provided by operations, and cash used by changes in operating assets and liabilities was $38.4 million. The changes in operating assets and liabilities included a $148.5 million decrease in inventories, a $63.2 million increase in accrued liabilities and a $17.6 million increase in accounts payable. Offsetting these amounts was a $125.4 million increase in prepaid expenses and other assets, a $51.5 million increase in accounts receivable and $14.0 million in net changes in income taxes, including excess tax benefits and deferred income taxes. The decrease in inventory was due to a planned inventory reduction of our acquired inventory to manage working capital needs. The increase in accrued liabilities was primarily a result of increased salary and benefits due to a larger workforce. The increase in accounts payable was due to the increase in expenses related to the post-acquisition operations. The increase in prepaid expenses and other assets was primarily due to amounts paid for transitional service arrangement fees, working capital adjustments and other HIS-related amounts. The increase in accounts receivable is due to the increase in revenue. The net changes in income taxes was a result of the timing of payments.
Our net cash provided by operations for the nine months ended September 30, 2016 was $68.7 million. Net income plus adjustments for non-cash net expenses contributed $79.0 million to cash provided by operations, and cash used by changes in operating assets and liabilities was $10.3 million. The changes in operating assets and liabilities included a $7.3 million decrease in accrued liabilities, a $6.6 million increase in inventories, a $2.2 million increase in prepaid expenses and other assets, and a $1.6 million decrease in accounts payable, partially offset by a $4.7 million increase in accounts receivable and $2.7 million in net changes to income taxes and deferred income taxes. The decrease in accrued liabilities was primarily due to the pay-out of fiscal year 2015 accrued bonuses in February of 2016, the payment of accrued restructuring charges related to the closure of our Slovakian manufacturing facility and the payment of acquisition-related accruals from our 2015 EXC acquisition. The increase in inventories was primarily due to building finished good safety stock, to support better customer deliveries, raw materials related to our Slovakia plant closure, and related transfer to our Mexico plant, and inventory associated with the acquired SwabCap product-line. The increase in prepaid expenses and other assets was primarily due to repayment of state aid and interest related to the closure of our Slovakian manufacturing facilities. The decrease in accounts payable was a result of the timing of disbursements. The increase in accounts receivable was due to an increase in revenue. The net changes in income taxes was a result of the timing of payments for cash tax purposes, which includes true-ups for 2015 overpayment and 2016 estimated taxes.
35

Table of Contents
Cash Flows from Investing Activities
The following table summarizes the changes in our investing cash flows (in thousands):

| Nine Months Ended September 30, |  |  |
| 2017 |  | 2016 |  | Change |
Investing Cash Flows: |  |  |  |  |  |
Purchases of property and equipment | $ | (51,702 | ) |  | $ | (15,018 | ) |  | $ | (36,684 | ) | (1)
Proceeds from sale of assets | 2 |  |  | 1 |  |  | 1 |  |
Business acquisitions, net of cash acquired | (157,097 | ) |  | (2,584 | ) |  | (154,513 | ) | (2)
Intangible asset additions | (3,718 | ) |  | (861 | ) |  | (2,857 | ) |
Purchases of investment securities | (24,743 | ) |  | (111,575 | ) |  | 86,832 |  | (3)
Proceeds from sale of investment securities | — |  |  | 45,429 |  |  | (45,429 | ) | (4)
Net cash (used in) provided by investing activities | $ | (237,258 | ) |  | $ | (84,608 | ) |  | $ | (152,650 | ) |

______________________________
(1) Our purchases of property and equipment will vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities. The year-over-year increases primarily related to HIS entities.

(2) | Our business acquisitions will vary from period to period based upon our current growth strategy and our ability to execute on desirable target companies. On February 3, 2017, we acquired HIS for $260 million in cash consideration (net of working capital adjustments), financed with existing cash balances and a three-year interest-only seller note of $75 million and we delivered 3.2 million shares of our common stock to Pfizer.

(3) | Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and due to changes in our investment strategy. In December 2016, we liquidated all of our investment securities to use the proceeds to fund the acquisition of HIS. In September 2017, we began to purchase investment securities in accordance with our investment policy.

(4) In December 2016, we liquidated all of our investment securities and used the proceeds to fund the acquisition of HIS. Accordingly, we did not have an investment balance until purchases were made in September 2017 and we have not had any investment sales during the nine months ended September 30, 2017.
While we can provide no assurances, we estimate that our capital expenditures in 2017 will approximate $80 million. In January 2017, we completed an expansion of our Mexico manufacturing plant. We anticipate making additional investments in molds, machinery and equipment in our manufacturing operations in the United States and Mexico to support new and existing products and in IT to benefit world-wide integrated operations. We expect to use our cash to fund our capital purchases. Amounts of spending are estimates and actual spending may substantially differ from those amounts.
36

Table of Contents
Cash Flows from Financing Activities
The following table summarizes the changes in our financing cash flows (in thousands):

| Nine Months Ended September 30, |  |  |
| 2017 |  | 2016 |  | Change |
Financing Cash Flows: |  |  |  |  |  |
Proceeds from exercise of stock options | $ | 19,967 |  |  | $ | 15,830 |  |  | $ | 4,137 |  | (1)
Proceeds from employee stock purchase plan | 2,705 |  |  | 2,361 |  |  | 344 |  |
Purchase of treasury stock | (3,951 | ) |  | (17,155 | ) |  | 13,204 |  | (2)
Net cash provided by (used in) financing activities | $ | 18,721 |  |  | $ | 1,036 |  |  | $ | 17,685 |  |

______________________________
(1) Proceeds from the exercise of stock options will vary from period to period based on the volume of options exercised and the exercise price of the specific options exercised.
(2) During the nine months ended September 30, 2017, our employees surrendered 27,129 shares of our common stock from vested restricted stock awards as consideration for approximately $4.0 million in minimum statutory withholding obligations paid on their behalf.
In July 2010, our Board of Directors approved a share purchase plan to purchase up to $40.0 million of our common stock. As of September 30, 2017, we had purchased $32.8 million of our common stock pursuant to this plan, leaving a balance of $7.2 million available for future purchases. This plan has no expiration date. We are currently limited on share purchases in accordance with the terms and conditions of our senior note with Pfizer (see Note 15: Long-Term Obligations in our accompanying condensed consolidated financial statements).
After our acquisition of the HIS business, we continue to maintain a substantial cash position. Cash generated includes stock sales, principally from the exercise of employee stock options. We maintain this position to fund our growth, meet increasing working capital requirements, and fund capital expenditures and to take advantage of acquisition opportunities that may arise.
As of September 30, 2017, we had $82.2 million of cash and cash equivalents held in local currency by our foreign subsidiaries. If these funds were needed for our operations in the U.S., we would be required to accrue and pay U.S. taxes for a portion of any repatriated funds. However, we expect to permanently reinvest these funds outside of the U.S. and, based on our current plans, we do not presently anticipate a need to repatriate them to fund our U.S. operations.
We believe that our existing cash and cash equivalents along with funds expected to be generated from future operations will provide us with sufficient funds to finance our current operations for the next twelve months. In the event that we experience downturns or cyclical fluctuations in our business that are more severe or longer than anticipated or if we fail to achieve anticipated revenue and expense levels, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all.
On November 8, 2017, we entered into a new five-year Senior Secured Revolving Credit Facility ("Credit Facility") with various lenders for $150 million, with Wells Fargo Bank, N.A. as the administrative agent. The Credit Facility has an accordion feature that would enable us to increase the borrowing capacity of the credit facility by the greater of (i) $100 million and (ii) 2.00x Total Leverage. Under the terms of the facility we will be subject to certain financial covenants pertaining to leverage and fixed charge coverage ratios. Borrowings under the Credit Facility will bear interest at LIBOR plus an applicable margin tied to the leverage ratio in effect. The unused portion of the Credit Facility will be subject to a per annum commitment fee which is also calculated using the leverage ratio in effect.
Off Balance Sheet Arrangements
In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.
37

Contractual Obligations
Our contractual obligations increased significantly due to the acquisition of HIS. The following table summarizes our contractual obligations, excluding open orders for purchases that support normal operations, as of September 30, 2017 (in thousands):

| Payments Due By Period
| Total |  | Remainder of 2017 |  | 2018 |  | 2019 |  | 2020 |  | 2021 |  | Thereafter
Long-term debt obligations | $ | 75,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 75,000 |  |  | $ | — |  |  | $ | — |
Interest payments on long-term debt obligations | 7,475 |  |  | 763 |  |  | 3,198 |  |  | 3,215 |  |  | 299 |  |  |  |  | — |
Operating lease obligations | 33,763 |  |  | 2,638 |  |  | 9,208 |  |  | 5,769 |  |  | 3,378 |  |  | 3,219 |  |  | 9,551 |
Purchase obligations(1) | 97,970 |  |  | 5,513 |  |  | 4,477 |  |  | 14,005 |  |  | 34,757 |  |  | 39,218 |  |  | — |
Total contractual obligations | $ | 214,208 |  |  | $ | 8,914 |  |  | $ | 16,883 |  |  | $ | 22,989 |  |  | $ | 113,434 |  |  | $ | 42,437 |  |  | $ | 9,551 |

___________________________________
(1) Purchase obligations includes agreements to purchase goods that are enforceable and legally binding. These amounts are not accrued as of September 30, 2017. It does not include milestone payments where payments may be refundable unless regulatory approval is obtained.
Description of Indebtedness
Senior Note
We entered into a senior note with Pfizer on February 3, 2017 to partially finance the HIS business acquisition and pay interest on that note based on LIBOR plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter.
At September 30, 2017, we had $75.0 million in principal outstanding under the senior note. The senior note is a three-year interest-only note and matures on February 3, 2020.
On November 8, 2017, we fully repaid the $75 million in outstanding principal under the senior note payable to Pfizer.
Critical Accounting Policies
In our Annual Report on Form 10-K for the year ended December 31, 2016, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements. Other than the addition of the business combination critical accounting policy below we have not changed our policies from those previously disclosed in our Annual Report.
Business Combinations
The allocation of the purchase price for acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed based on their respective fair values.
New Accounting Pronouncements
See Note 2 to Part I, Item 1. Financial Statements.
38

Table of Contents
Forward Looking Statements
Various portions of this Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, and documents referenced herein, describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future. These statements about the future are “forward looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we may identify them by using words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "will," "continue," "could," "may," and by similar expressions and statements about aims, goals and plans. The forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable, but we do not intend the statements to be representations as to future results. They include, without limitation, statements about:

• | future growth; future operating results and various elements of operating results, including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts; future sales and unit volumes of products; expected increases and decreases in sales; deferred revenue; accruals for restructuring charges, future license, royalty and revenue share income; production costs; gross margins; litigation expense; future SG&A and R&D expenses; manufacturing expenses; future costs of expanding our business; income; losses; cash flow; amortization; source of funds for capital purchases and operations; future tax rates; alternative sources of capital or financing; changes in working capital items such as receivables and inventory; selling prices; and income taxes;

• | factors affecting operating results, such as shipments to specific customers; reduced dependence on current proprietary products; loss of a strategic relationship; change in demand; domestic and international sales; expansion in international markets, selling prices; future increases or decreases in sales of certain products and in certain markets and distribution channels; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations; increases in systems capabilities; introduction, development and sales of new products, acquisition and integration of businesses and product lines, including the HIS business, SwabCap (EXC) and Tangent; benefits of our products over competing systems; qualification of our new products for the expedited Section 510(k) clearance procedure; possibility of lengthier clearance process for new products; planned increases in marketing; warranty claims; rebates; product returns; bad debt expense; amortization expense; inventory requirements; lives of property and equipment; manufacturing efficiencies and cost savings; unit manufacturing costs; establishment or expansion of production facilities inside or outside of the United States; planned new orders for semi-automated or fully automated assembly machines for new products; adequacy of production capacity; results of R&D; our plans to repurchase shares of our common stock; asset impairment losses; relocation of manufacturing facilities and personnel; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies; the effect of costs to customers and delivery times; business seasonality and fluctuations in quarterly results; customer ordering patterns and the effects of new accounting pronouncements; and

• | new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; loss of larger distributors and the ability to locate other distributors; the impact of our acquisition of the HIS business; growth of our Clave products in future years; design features of Clave products; the outcome of our strategic initiatives; regulatory approvals and compliance; outcome of litigation; patent protection and intellectual property landscape; patent infringement claims and the impact of newly issued patents on other medical devices; competitive and market factors, including continuing development of competing products by other manufacturers; improved production processes and higher volume production; innovation requirements; consolidation of the healthcare provider market and downward pressure on selling prices; distribution or financial capabilities of competitors; healthcare reform legislation; use of treasury stock; working capital requirements; liquidity and realizable value of our investment securities; future investment alternatives; foreign currency denominated financial instruments; foreign exchange risk; commodity price risk; our expectations regarding liquidity and capital resources over the next twelve months; capital expenditures; plans to convert existing space; acquisitions of other businesses or product lines, indemnification liabilities and contractual liabilities.

Forward-looking statements involve certain risks and uncertainties, which may cause actual results to differ materially from those discussed in each such statement. First, one should consider the factors and risks described in the statements themselves or otherwise discussed herein. Those factors are uncertain, and if one or more of them turn out differently than we currently expect, our operating results may differ materially from our current expectations.
39

Table of Contents
Second, investors should read the forward looking statements in conjunction with the Risk Factors discussed in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2016, Part II, Item 1A of this Quarterly Report on Form 10-Q and our other reports filed with the SEC. Also, actual future operating results are subject to other important factors and risks that we cannot predict or control, including without limitation, the following:

• | general economic and business conditions, both in the U.S. and internationally;

• | unexpected changes in our arrangements with Pfizer or our other large customers;

•outcome of litigation;
•fluctuations in foreign exchange rates and other risks of doing business internationally;
•increases in labor costs or competition for skilled workers;
•increases in costs or availability of the raw materials need to manufacture our products;
•the effect of price and safety considerations on the healthcare industry;
•competitive factors, such as product innovation, new technologies, marketing and distribution strength and price erosion;
•the successful development and marketing of new products;
•unanticipated market shifts and trends;
•the impact of legislation affecting government reimbursement of healthcare costs;

• | changes by our major customers and independent distributors in their strategies that might affect their efforts to market our products;

•the effects of additional governmental regulations;
•unanticipated production problems; and
•the availability of patent protection and the cost of enforcing and of defending patent claims.
The forward-looking statements in this report are subject to additional risks and uncertainties, including those detailed from time to time in our other filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof and, except as required by law, we undertake no obligation to update or revise any of them, whether as a result of new information, future events or otherwise.

Item 3. | Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risk stemming from changes in interest rates and foreign currency exchange rates.
Interest Rate Risk
Our market risk on interest rates relates to a $75 million senior note with Pfizer that we entered in to on February 3, 2017 to partially fund the HIS business acquisition. We pay interest on that note based on LIBOR plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter. We are exposed to interest rate risk from changes in interest rates. We use a sensitivity analyses to measure our interest rate risk exposure.
If the LIBOR rate increases or decreases 1% from September 30, 2017, the additional annual interest expense or savings would amount to $0.8 million.
Foreign Exchange Risk
We have foreign currency exchange risk related to foreign-denominated cash, accounts receivable and accounts payable and accrued liabilities. In our European operations, our net Euro asset position at September 30, 2017 was approximately €48.7 million. A 10% change in the conversion of the Euro to the U.S. dollar for our cash, accounts receivable, accounts payable and accrued liabilities from the September 30, 2017 spot rate would impact our consolidated amounts on these balance sheet items by approximately $5.8 million, or 2.7% of these consolidated net assets. We expect that in the future, with the growth of our European distribution operations, net Euro denominated instruments will continue to increase. We currently do not hedge our Euro foreign currency exposures.
40

Table of Contents

Item 4. | Controls and Procedures

Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.
Changes in Internal Control Over Financial Reporting
On February 3, 2017, we completed our acquisition of HIS. As the acquisition occurred in the first quarter of 2017, the scope of our evaluation of the effectiveness of internal control over financial reporting does not include HIS. This exclusion is in accordance with the SEC's general guidance that an assessment of a recently acquired business may be omitted from our scope for a period not to exceed one year from the date of the acquisition.
There was no change in our internal control over financial reporting during the quarter ended September 30, 2017 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting, except as mentioned above.
PART II - OTHER INFORMATION

Item 1. | Legal Proceedings

Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer, Inc. subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that the defendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS stock and asset purchase agreement (“SAPA”).
In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira, Inc. requesting that the company provide information regarding certain business practices in the intravenous solutions part of the HIS business. Separately, in April 2017, we received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoena calls for production of documents related to the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is the subject of cross-claims for indemnification by both us and Pfizer under the SAPA. We will coordinate with Pfizer to produce records to the New York Attorney General and the Department of Justice.
In addition to the legal matter described above, we are from time to time involved in various other legal proceedings, either as a defendant or plaintiff, most of which are routine litigation in the normal course of business. We believe that the resolution of the legal proceedings in which we are involved will not have a material adverse effect on our financial position or results of operations.
41

Table of Contents

Item 1A. | Risk Factors

In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2016, as well as the information contained in this Quarterly Report and our other reports and registration statements filed with the SEC.
The HIS business acquisition has resulted in organizational change and significant growth to our business. If we fail to effectively manage this growth and change to our business in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed.
The HIS business has resulted in significant growth in our personnel and operations, adding approximately 4,300 employees to our headcount, bringing our total headcount as of September 30, 2017 to approximately 7,000 employees. In addition, the acquisition process and other events prior to our acquisition put a significant strain on certain HIS business customer relationships. We will continue to incur significant expenditures and the allocation of management time to assimilate the HIS business employees in a manner that preserves the key aspects of our corporate culture, including a focus on strong customer satisfaction, but there can be no assurance that we will be successful in our efforts. If we do not effectively integrate, train and manage our combined employee base and maintain strong customer relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations.
There have been no other material changes in the risk factors other than those mentioned above from those previously disclosed under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2016.

Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds

Purchase of Equity Securities
The following is a summary of our stock repurchasing activity during the third quarter of 2017:

Period |  | Total number of shares purchased |  | Average price paid per share |  | Total number of shares purchased as part of a publicly announced program |  | Approximate dollar value that may yet be purchased under the program(1)
07/01/2017 — 07/31/2017 |  | — |  |  | $ | — |  |  | — |  |  | $ | 7,169,000 |
08/01/2017 — 08/31/2017 |  | — |  |  | $ | — |  |  | — |  |  | $ | 7,169,000 |
09/01/2017 — 09/30/2017 |  | — |  |  | $ | — |  |  | — |  |  | $ | 7,169,000 |
Third quarter of 2017 total |  | — |  |  | $ | — |  |  | — |  |  | $ | 7,169,000 |

____________________________

(1) | Our common stock purchase plan, which authorized the repurchase of up to $40.0 million of our common stock, was authorized by our Board of Directors and publicly announced on July 19, 2010. This plan has no expiration date. We are not obligated to make any purchases under our stock purchase program. Subject to applicable state and federal corporate and securities laws, purchases under a stock purchase program may be made at such times and in such amounts as we deem appropriate. Purchases made under our stock purchase program can be discontinued at any time we feel additional purchases are not warranted.

42

Table of Contents
Item 6. Exhibits
See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.
43

Table of Contents
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ICU Medical, Inc.

(Registrant) |  |
/s/ Scott E. Lamb | Date: | November 9, 2017
Scott E. Lamb |  |
Chief Financial Officer |  |
(Principal Financial Officer) |  |

44

Exhibit Index

Exhibit 10.1 |  | Credit Agreement, dated as of November 8, 2017, among ICU Medical, Inc., as borrower, certain lenders party thereto and Wells Fargo Bank, N.A., as administrative agent and swingline lender.
Exhibit 31.1 |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2 |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1 |  | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 101.INS |  | XBRL Instance Document
Exhibit 101.SCH |  | XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document

45